Health economics and cervical cancer prevention: A global perspective

Virus Research

Volumn 89, Issue 2, 2002, Pages 301-309

  Goldie, Sue J ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Cervical cancer; Cost effectiveness analysis; Mathematical models; Public health policy

Indexed keywords

VIRUS DNA;

BIOLOGY; CANCER CONTROL; CANCER MORTALITY; CANCER PREVENTION; CANCER SCREENING; CONFERENCE PAPER; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DEMOGRAPHY; ECONOMIC ASPECT; EMPIRICISM; FEASIBILITY STUDY; HEALTH CARE POLICY; HUMAN; INVESTMENT; MATHEMATICAL MODEL; MEDICAL DECISION MAKING; MEDICAL RESEARCH; METHODOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH; RESOURCE MANAGEMENT; SOUTH AFRICA; TECHNOLOGY; UNITED STATES; UTERINE CERVIX CANCER; WART VIRUS;

COST-BENEFIT ANALYSIS; FEMALE; HEALTH POLICY; HUMANS; MODELS, BIOLOGICAL; PUBLIC HEALTH; SOUTH AFRICA; UNITED STATES; UTERINE CERVICAL NEOPLASMS;

EID: 0036849817     PISSN: 01681702     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-1702(02)00199-5     Document Type: Conference Paper

References (34)

1. Bosch F.X., Lorincz A., Munoz N., Meijer C.J.L.M., Shah K.V. The causal relationship between human papillomavirus and cervical cancer. J. Clin. Pathol. 55:2002;244-265.
2. Brown A.D., Garber A.M. Cost-effectiveness of 3 methods to enhance the sensitivity of Papanicolaou testing. JAMA. 281:1999;347-353.
3. Cuzick J., et al. Human papillomavirus testing for cervical screening. Health Technol. Assess. 3:1999;14.
4. Drummond M., Stoddart G., Torrance G. Methods for the Economic Evaluation of Health Care Programs. Second Ed. 1997;Oxford University Press, Oxford.
5. Eddy D.M. Screening for cervical cancer. Ann. Intern. Med. 113:1990;214-226.
6. Fahs M.C., Mandelblatt J., Schechter C., Muller C. Cost effectiveness of cervical cancer screening for the elderly. Ann. Intern. Med. 117:1992;520-527.
7. Franco E.L., Rohan T.E., Villa L.L. Epidemiologic evidence and human papillomavirus infection as a necessary cause of cervical cancer. J. Natl. Cancer Inst. 91:1999;506-511.
8. Gold M.R., Siegel J.E., Russel L.B., Weinstein M.C., Cost-Effectiveness in Health and Medicine. 1996;Oxford University Press, New York.
9. Goldie S.J., Freedberg K.A., Weinstein M.C., Wright T.C., Kuntz K.M. Cost effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the human immunodeficiency virus. Am. J. Med. 111:2001;140-149.
10. Goldie S.J., Kuhn L., Denny L., Pollack A., Wright T.C. Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. JAMA. 285:(24):2001;3107-3115.
11. Goldie S.J., Weinstein M.C., Kuntz K.M., Freedberg K.A. The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women. Ann. Intern. Med. 130:1999;97-107.
12. Gustafsson L., Adami H.O. Optimization of cervical cancer screening. Cancer Causes Control. 3:1992;125-136.
13. Habbema J.D.F., van Oortmarssen G.J., Lubbe J., Th N., van der Maas P.J. Computer Methods Programs Biomedicine. 20:1984;79-83.
14. Halpern M.T., Luce B.R., Brown R.E., Geneste B. Health and economic outcomes modeling practices: a suggested framework. Value in Health. 2:1998;131-147.
15. International Agency for Research on Cancer . IARC monographs on the evaluation of carcinogenic risks to humans. Human Papillomaviruses. 64:1995;International Agency for Research on Cancer, Lyon, France.
16. Jenkins D., Sherlaw-Johnson C., Gallivan S. Can papilloma virus testing be used to improve cervical cancer screening? Int. J. Cancer. 65:(6):1996;768-773.
17. Kim J., Wright T.C., Goldie S.J. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. JAMA. 287:2002;2382-2390.
18. Mandelblatt, J., Lawrence, W.F., Wamack, S.M., et al., 2002. Benefits and costs of using HPV testing to screen for cervical cancer. JAMA 287, 2372-2381.
19. McCrory, D., Mather, D., Bastain, L., et al., 1999. Evaluation of Cervical Cytology. Evidence Report/Technology Assessment No.5 (Prepared by Duke University under Contract No. 290-97-0014). AHCPR Publication No. 99-E010. Rockville, MD, Agency for Health Care Policy and Research.
20. Miller B.A., Kolonel L.N., Bernstein L., et al. Racial/Ethnic Patterns of Cancer in the United States 1988-1992. 1998;US Department of Health and Human Services, National Institutes of Health, Bethesda, MD.
21. Myers E., McCrory D., Nanda K., Matchar D. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am. J. Epidemiol. 151:2000;1158-1171.
22. Parkin D.M., Pisani P., Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int. J. Cancer. 80:1999;827-841.
23. Pecorelli S., Benedet J.L., Creasman W.T., Shepherd J.H. FIGO staging of gynecologic cancer. 1994-1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics. In. J. Gynaecol. Obstet. 65:1999;243-249.
24. Pisani P., Parkin D., Munoz N., et al. Cancer and infection: estimates of the attributable fraction in 1990. Cancer Epidemiol. Biomarkers Prev. 6:1997;387-400.
25. Pisani P., Parkin D.M., Bray F., Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int. J. Cancer. 83:1999;18-29.
26. Ponten J., Adami H.O., Bergstrom R., Dillner J., Friberg L.G., et al. Strategies for global control of cervical cancer. Int. J. Cancer. 60:1995;1-26.
27. Sankaranarayanan R., Black R.J., Swaminathan R., et al. An overview of cancer survival in developing countries. IARC Sci. Publ. 145:1998;135-173.
28. Sherlaw-Johnson C., Gallivan S., Jenkins D., Jones M.H. Cytological screening and management of abnormalities in prevention of cervical cancer: an overview with stochastic modelling. J. Clin. Pathol. 47:1994;430-435.
29. Sherlaw-Johnson C., Gallivan S., Jenkins D. Evaluating cervical cancer screening programmes for developing countries. Int. J. Cancer. 72:(2):1997;210-216.
30. Solomon D., Davey D.D., Moriarty A., et al. The 2001 Bethesda System terminology for reporting results of cervical cytology. JAMA. 287:2002;2114-2119.
31. Surveillance, Epidemiology, End Results (SEER) Cancer Statistics Review, 1973-1994. US Dept of Health and Human Services, PHS, NIH, NCI, Bethesda, Maryland. SEER Home Page, Available from http://www-seer.ims.nci.nih.gov/ National Cancer Institute; 1997.
32. van Ballegooijen M., van den Akker-van Marle M.E., Warmerdam P.G., et al. Present evidence on the value of HPV testing for cervical cancer screening: a model-based exploration of the (cost-) effectiveness. Br. J. Cancer. 76:(5):1997;651-657.
33. van den Akker-van Marle M.E., van Ballegooijen M., van Oortmarssen G.J., et al. Cost-effectiveness of cervical cancer screening: comparison of screening policies. J. Natl. Cancer Inst. 94:2002;193-204.
34. Wright T.C. Jr., Cox J.T., Massad L.S., et al. 2001 Consensus guidelines for the management of women with cervical cytological abnormalities. JAMA. 287:2002;2120-2129.